Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc)

DUBLIN, Feb. 8, 2024 /PRNewswire/ -- The "Global Markets for Vaccine Technologies" report has been added to ResearchAndMarkets.com's offering. Advancements will occur in regard to the development of novel vaccines towards emerging infectious diseases, cancers and allergies. Continuous improvements in vaccine design, delivery technologies and manufacturing will also boost market growth. The global vaccine technologies market is segmented in this report by technology, disease, age, and region. This report explains critical trends in the vaccine industry. It discusses the market determinants, which act as motivating or restraining factors and provides insights to stakeholders and potential entrants. This report includes only human vaccines; animal vaccines have not been considered in this report. This study looks at research and development (R&D) spending, increasing competition and new technologies, which are giving direction to the market. These advancements, new product launches and changing lifestyles are influencing future market growth. Company mergers, acquisition strategies and collaborations are also covered in this report. Additionally, this study discusses the strengths and weaknesses of each strategy type, considering new technologies, growing competition and changing customer needs. The market has been analyzed based on the application of current vaccines. Categories considered in this report include pneumococcal vaccines; diphtheria, tetanus vaccines; HPV vaccines; MMR vaccines; and other vaccines including rotavirus vaccines, influenza vaccines, hepatitis B vaccines, chickenpox vaccines, polio vaccines, BCG, and yellow fever vaccines. This study details market growth among vaccine manufacturers and end users. Genomic research centers, academic institutions, government and private laboratories, various hospital settings, and pharmaceutical, diagnostic and biotechnology companies and physicians will find this study to be of interest. This report provides useful information to all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this study useful. The Report Includes 34 data tables and 63 additional tables An up-to-date overview of the global markets for vaccine technologies Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028 Estimate of the market size and revenue forecast for the global market, and a corresponding market share analysis based on technology, disease indication, age group and region Facts and figures pertaining to the market drivers, opportunities and challenges, emerging technologies, global R&D spending, and the regulatory landscape Assessment of present and future strategies in the innovation-driven vaccine technologies market, and a look at the vaccines for humans and their immunization schedule Discussion of the importance of ESG in the market for vaccine technologies, including consumer attitudes, the impact of ESG factors on company performance, and ESG practices of leading companies Review of patents and patent applications Overview of the major vendors, along with an analysis of the industry structure, including company market shares, recent M&A activity, and venture funding Analysis of the competitive landscape based on recent developments and segmental revenues Profiles of the leading companies Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market and Technology Background Immune System and Vaccines Components of the Immune System Cells of the Immune System Immune Response Major Histocompatibility Complex (MHC) Immunization and Vaccines Disorders of the Immune System Impact of Lifestyle on the Immune System How Vaccines Work Principles of Immunization Types of Immunity Advantages of Vaccination History of Vaccines Vaccines and Immunization, Overview Types of Vaccines Attenuated (Live) Vaccines Inactivated (Killed) Vaccines Toxoid Vaccines Subunit Vaccines Conjugate Vaccines Recombinant Vector Vaccines DNA Vaccines RNA Vaccines Immunization Advantages of Immunization Adjuvants and Excipients Pathogen Components Particulate Adjuvants Infectious Diseases Preventable by Vaccine Human Diseases Viral Diseases Bacterial Diseases Regulatory Aspects World Health Organization (WHO) Prequalified Vaccines New Product Approvals Recalls Significant Regulatory Developments in Vaccines Chapter 4 Market Dynamics Market Drivers Growing Awareness of Immunization Growing Investments and R&D New Vaccines Prevalence of Infectious Diseases Market Restraints Vaccine Development and Pricing Market Opportunities Increased Demand from Emerging Markets Therapeutic Vaccines Chapter 5 Global Market for COVID-19 Vaccines COVID-19 Vaccine Technologies Advent of mRNA Technology Impact of COVID-19 on Routine Infant Vaccination COVID-19 Disruptions Stagnating Global Coverage Rate Progress and Challenges by Country and Region Chapter 6 Market Breakdown by Technology Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines Live-Attenuated Vaccines Inactivated Vaccines Toxoid Vaccines Other/Combination Vaccines Chapter 7 Market Breakdown by Disease Pneumococcal Diphtheria and Tetanus HPV MMR Chapter 8 Market Breakdown by Age Group Pediatrics Adolescents and Adults Chapter 9 Market Breakdown by Region Chapter 10 Emerging Technologies and Developments Developments mRNA Vaccines Viral Vector Vaccines Nanoparticle Vaccines DNA Vaccines Virus-Like Particle (VLP) Vaccines Self-Amplifying RNA Vaccines Innovative Adjuvants AI and Computational Biology Personalized Vaccines Plant-Based Vaccines Chapter 11 Competitive Landscape Chapter 12 Company Profiles Abbott Astrazeneca Bavarian Nordic Bharat Biotech International Emergent Biosolutions GSK Johnson & Johnson Services Merck Mitsubishi Tanabe Pharma Corp. Panacea Biotec Pfizer Inc. Sanofi For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

Experts at Cincinnati Children's and Children's Hospital Colorado say findings could enable more at-risk children to be protected from measles, mumps, and chicken pox CINCINNATI, Oct. 16, 2023 /PRNewswire/ -- Live vaccinations provided to children who previously received liver or kidney transplants were found to be safe and prompted an immune response to guard against several life-threatening conditions, according to a new study published Oct. 12, 2023, in JAMA Network Open. Continue Reading A liver-transplant recipient receives the MMR vaccine at Cincinnati Children’s. The study involving 18 U.S. institutions that perform organ transplants included 281 children on chronic immunosuppressive medications. (Credit: Family provided photo) The study, based on data from 18 organ transplant centers, was co-authored by Lara Danziger-Isakov, MD, MPH, interim director of the Division of Infectious Diseases at Cincinnati Children's, and Amy Feldman, MD, MSCS, medical director of the Liver Transplant Program at Children's Hospital Colorado. The results are important because the rates of measles, mumps and the varicella-zoster virus that causes chicken pox are rising nationally and internationally, leaving immunocompromised children at risk for life-threatening conditions, according to Danziger-Isakov, senior author of the study. "This shifts the paradigm of the approach to protecting this vulnerable population where live viral vaccines were previously avoided," Danziger-Isakov says. "This should enable children who have received organ transplants to integrate into their communities with more confidence and decreased risk for acquiring chicken pox or measles, which have both made a resurgence." Global surges of measles and mumps were exacerbated by decreasing herd immunity as millions of vaccine doses were missed during the COVID-19 pandemic, leaving nonimmune organ transplant recipients at significant risk for community exposure, infection, disease and death from wild-type infection, says Feldman, first author of the study. "Community acquisition of measles and varicella is a real risk for immunocompromised children in today's world," Feldman says. "These infections can be fatal in transplant recipients. Being able to administer live vaccines post-transplant, and provide immunity, is critical." Historically, live vaccines to guard against measles, mumps, rubella (MMR) and varicella-zoster virus (VZV) have not been recommended after solid organ transplant due to concerns about a theoretical risk of vaccine strain infection in immunocompromised children. However, the authors reported no serious adverse events observed following the live vaccination of the children enrolled in the trial between Jan. 1, 2002, and Feb. 28, 2023. Transplant recipients who participated in the trial received one to three doses of MMR vaccine and/or one to three doses of VZV vaccine. The cohort included 281 children on chronic immunosuppressive medications with a median age of 8.9 years at the time of the first post-transplant vaccine. The median time from transplant to enrollment in the study was 6.3 years. Safety data were collected after each vaccination, and antibody levels were measured at zero to three months and one year after vaccination. The majority of children developed protective antibodies following vaccination – 72% for varicella, 86% for measles, 83% for mumps and 99% for rubella. One year after vaccination, the majority of children who developed protective antibodies maintained that protection – 77% for varicella, 92% for measles, 83% for mumps and 94% for rubella. Five children developed clinical varicella, but all of their conditions resolved within one week. The findings suggest that live vaccinations may be safe and immunogenic after solid organ transplant in select pediatric recipients and can offer protection against circulating measles, mumps and varicella. Further research is needed to understand long-term maintenance of immunity after vaccination of children who receive organ transplants, as well as factors associated with immune response and clinical protection, the authors noted. Feldman reported that she is funded by a K08 grant (HS026510) from the Agency for Healthcare Research and Quality. Danziger-Isakov reported receiving clinical research support paid to her institution from AiCuris, Ansun Biopharma, Astellas Pharma, Merck, Pfizer and Takeda; advisory board fees from GlaxoSmithKline and Roche; and consultant fees from Merck outside the submitted work. About Cincinnati Children's Cincinnati Children's ranks No. 1 in the nation in U.S. News & World Report's 2023-24 listing of Best Children's Hospitals. In addition, Cincinnati Children's is recognized as one of America's Most Innovative Companies by Fortune. Nearly one-third of the health system's 18,500 employees are engaged in research, and Cincinnati Children's is one of the top two recipients of pediatric research grants from the National Institutes of Health. Additional information may be found at SOURCE Cincinnati Children's Hospital Medical Center